



Date: 15 November 2024

To,
Corporate Relationship Department,
BSE Limited
PJ Towers, Dalal Street,
Mumbai 400001, MH

Stock Code: 542248

Subject: Press Release

Dear Sir/Madam,

Further to our previous letter for the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter ended 30 September 2024, we are enclosing a copy of the Press Release for your records.

The above information is being hosted on the Company's website www.deccanhealthcare.co.in in terms of Regulation 46 of the Listing Regulations, as amended.

We request you to kindly take the same on records.

Thanking You,
For and on behalf of
Deccan Health Care Limited

Vaishali Gagnani
Company Secretary &
Compliance Officer

Encl: A/a

Registered Office:
6-3-347/17/5/A/Back Position,
Dwarakapuri Colony, Punjagutta,
Hyderabad – 500082, Telangana, India
Email: info@deccanhealthcare.co.in
Tel: +91 40 4709 6427

Innovation Hub & Manufacturing:
Plot No.13, Sector 03, IIE Pant Nagar,
SIDCUL, Udham Singh Nagar – 263153,
Uttarakhand, India
CIN: L72200TG1996PLC024351
www.deccanhealthcare.co.in

Deccan Health Care Posts Strong Q2 FY25 Growth: 25% Revenue Jump, 27.5% EBITDA Rise, 45.6% PAT Growth

Hyderabad, 15th November 2024: Deccan Health Care Limited (BSE: 542248), a leading nutraceuticals product company, to help consumers age gracefully, reduce the risk of disease, prevent disease, and live a better quality of life, announced its unaudited financial results for the Q2 & H1 FY25 period which ended 30th September 2024.

Key Business Highlights:

▶ Quarterly Performance:

- Revenue increased by 25% QoQ to ₹1,882.1 lakhs, and by 9.5% YoY. Goss Profit grew by 18.2% QoQ and 8.8% YoY to ₹745.6 lakhs, with a margin of 39.6%.
- EBITDA improved by 27.5% QoQ and 7.7% YoY to ₹110.9 lakhs, while the EBITDA Margin was at 5.9%. PAT increased by 45.6% QoQ to ₹53.7 lakhs, with the PAT Margin of 2.9%.

▶ Half Yearly Performance:

- Revenue increased by 19.2% YoY to ₹3,388.2 lakhs, while Gross Profit showed a 9.2% YoY improvement, reaching ₹1,376.7 lakhs, though the Margin to 40.6%. EBITDA saw a modest 6.7% YoY increase, reaching ₹197.9 lakhs, with the EBITDA Margin at 5.8%. While PAT rose by 7.5% YoY to ₹90.6 lakhs.

▶ Tackling Anemia with Natural Solutions: Straya's Iron Fruit Bar and Collaborative Efforts:

- Straya – Bharpoor Iron Hardin, a 20g natural iron fruit bar, provides 9mg of iron from natural sources, enriched with over 13 herbs, seeds, and vegetables. This fruit bar offers a comfortable alternative to traditional iron supplements, supporting the Anemia Mukh Bharat (AMB) initiative.
- A multi-sectoral approach involving public health institutions, corporates, educational bodies, and local communities is crucial to addressing anemia. Partnerships with organizations like the Ganga Aruna Foundation, IFFCO TOKIO, the Child Unbound Foundation (through the founder of INOX Group), and various schools are helping extend the distribution of the natural iron fruit bar.

▶ Future Growth Engine:

- The growth momentum in demands is steadily accelerating, highlighting the increasing demand and acceptance of our products across diverse regions. We are focused on enhancing market share by expanding coverage through DWC & HS initiatives, boosting visibility nationwide.
- Our ongoing efforts in growing private label manufacturing are expected to reflect positively in the company's performance in upcoming quarters.

Standalone Financial Performance for Q2 & H1 FY25 (₹ in Lakh):

| Parameters | Q2 FY25 | Q1 FY25 | QoQ | Q2 FY24 | YoY | H1 FY25 | H1 FY24 | YoY | FY24 |
|---------------|---------|---------|---------|---------|----------|---------|---------|----------|---------|
| Revenue | 1,882.1 | 1,506.1 | 25.0% | 1,719.5 | 9.5% | 3,388.2 | 2,841.8 | 19.2% | 5,972.9 |
| EBITDA | 110.9 | 87.0 | 27.5% | 102.9 | 7.7% | 197.9 | 185.4 | 6.7% | 375.9 |
| EBITDA Margin | 5.9% | 5.8% | +12 bps | 6.0% | (9) bps | 5.8% | 6.5% | (68) bps | 6.3% |
| PAT | 53.7 | 36.9 | 45.6% | 52.9 | 1.5% | 90.6 | 84.3 | 7.5% | 152.2 |
| PAT Margin | 2.9% | 2.4% | +41 bps | 3.1% | (22) bps | 2.7% | 3.0% | (29) bps | 2.5% |

Commenting on the financial results, Dr. Minto Purshotam Gupta, Chairman & Managing Director of Deccan Health Care Limited said, *"We have delivered impressive growth in Q2 FY25, achieving a revenue of ₹1,882.1 lakhs, representing a 25% increase QoQ and a 9.5% rise YoY. This strong revenue performance is complemented by a 27.5% increase in EBITDA, reaching ₹110.9 lakhs, with an EBITDA margin of 5.9%, reflecting high demand, effective cost control, and continued operational efficiency. Furthermore, our PAT saw a remarkable 45.6% QoQ growth, with a PAT margin of 2.9%, highlighting improved bottom-line performance. We are witnessing positive demand momentum progress across all business segments.*

Looking ahead, we are focused on expanding our market share. We are working to increase our network across the country through DWC and HS, which will boost our visibility and market presence. Another important priority is growing our private-label manufacturing contracts, a strategy already underway that will positively impact our performance in the coming quarters, reflecting our commitment to sustainable growth. To our valued shareholders, we remain dedicated to delivering consistent returns and strengthening the company's position for future success."

About Deccan Health Care Limited (BSE: 542248):

Deccan Health Care Limited, established in 1996, is a leading nutraceutical company committed to helping consumers age gracefully and enhance their overall well-being. With a focus on innovation, supply chains, and brand equity, the company consistently delivers superior value to its customers. Popular for its Fast-Moving Consumer Healthcare products, including food pills and meals, Deccan Health Care Limited addresses 52+ wellness goals, preventing over 200+ diseases. The success of the BE YOUNG brand, particularly through e-commerce, reflects the company's dedication. Moreover, the international expansion with the STAY YOUNG brand further demonstrates its dynamic approach. Deccan Health Care Limited stands out as a positive force in the nutraceuticals industry, prioritizing consumer health and sustained growth.

Safe Harbor:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential, and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

| DECCAN HEALTH CARE LIMITED CIN: L72200TG1996PLC024351 | |
|--|--|
| Dr. Minto Purshotam Gupta Chairman & Managing Director E: cmd@deccanhealthcare.co.in W: www.deccanhealthcare.co.in | Mr. Ritesh Shashiprakash Singh Investor Relations Consultant, Rik Capital M: +91 83293 85762 E: ritesh.singh@rikcapital.in W: www.rikcapital.in |